The two technologies are different, but the goal of both is to provide a result within 40 minutes. The researchers say they are working with manufacturers to develop the products, which they hope will retail for $5 or less.
Baricitinib, also known under the brand name Olumiant, is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis.
State officials declined to provide details on specifically how the hotel is being used—including whether it is a treatment site for homeless individuals—to protect patient privacy.
The long-planned $500 million project is at a pivotal moment—one its organizers say could serve as a catalyst for tremendous growth at the 50-acre campus and for central Indiana overall.
Indiana has been undergoing a huge shift in psychiatric care in recent years, but still doesn’t have the resources to deal with patients suffering from ailments ranging from anxiety to schizophrenia.
Dr. Christopher Stobart and his students are focusing on an enzyme in the virus that could inhibit its replication, and plan to submit the findings to a virology journal in coming months.
The main manufacturer of a pesticide used for decades on a wide array of crops, including strawberries, corn and citrus, said Thursday it will stop making the product, which some activists have said is linked to neurological problems in children.
The report, issued Monday by researchers at the Fairbanks School of Public Health at IUPUI, is the latest commentary on Indiana’s poor report card on health care.
The Indianapolis drugmaker quietly terminated a collaboration with NextCure Inc. after spending $40 million on an up-front fee and equity investment, and with little to show from the partnership.
After raking in record amounts of venture capital funding in 2017 and 2018, Indiana life science companies saw funding drop last year by double-digits, while the average deal amount dipped sharply as well.
Dr. Anantha Shekhar, a nationally recognized health sciences researcher and entrepreneur, has played a major role in boosting research funding at IU, where he has worked since 1989 in numerous leadership roles.
The year didn’t feature any hostile takeovers or huge disasters. But a lot of companies made big strides in 2019, including Eli Lilly and Co., Corteva and Elanco. And many rejoiced when Washington ended a 2.3% tax on thousands of medical devices.
The repeal ends a 2.3% tax on thousands of medical devices, from stents and catheters to pacemakers and MRI machines. Indiana is home to 155 device-makers, ranging from small metal shops to multibillion-dollar manufacturers.
To satisfy House Democrats, the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less expensive knockoffs.
CEO Gail Boudreaux’s recent comments at a health care summit dampened speculation that Anthem might create its own physician group, something the insurer tried unsuccessfully two decades ago.
Neuropsychiatric Hospitals LLC said it is developing a 64-bed hospital in Greenwood that will serve patients with complex medical and psychiatric condition.
Fishers-based Aggressively Organic Inc., an agricultural technology company that focuses on alleviating food insecurity, announced plans in 2017 to hire 200 people by the end of 2021.
Medistar Corp. of Texas has filed an application to build a 42,610-square-foot building at 795 North Emerson Avenue, a vacant and undeveloped site about a mile south of Franciscan Health Indianapolis.
The expansion is the latest move by a large Indianapolis health system to expand cancer care, a fast-growing and competitive medical field.
Indianapolis-based Cornerstone Cos. has invested more than $84 million in recent years to buy medical office buildings, clinics and surgery centers. Now it is about to start its fifth investment fund.
